Biogen has added a preclinical-stage drug candidate for Parkinson's disease via a $722.5 million licensing agreement with Alectos Therapeutic, as it continues to rebuild a pipeline behind its side ...

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other genomics stocks. Genomics is the study of genes and how they function. Many rapidly growing ...

Biogen (BIIB) announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, rare neurological, and immunological diseases. As part of ...

Cambridge, Massachusetts-based Biogen Inc. (BIIB) discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. With a market cap of $26.6 bi ...

Biogen (NASDAQ:BIIB) has agreed to pay Neomorph up to $1.45B plus royalties on any future products as part of a new collaboration deal for the discovery and development of molecular glue degraders ...

Jefferies analyst Michael Yee maintained a Buy rating on Biogen (BIIB – Research Report) yesterday and set a price target of $250.00. Michael Yee’s rating is based on the promising data ...

Deep-pocketed investors have adopted a bearish approach towards Biogen (NASDAQ:BIIB), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

Oct 28 (Reuters) - Biogen (BIIB.O), opens new tab said on Monday insider Robin Kramer will take over as the drugmaker's finance chief after incumbent Michael McDonnell retires at the end of ...

Biogen Inc. (BIIB) came out with quarterly earnings of $4.08 per share, beating the Zacks Consensus Estimate of $3.77 per share. This compares to earnings of $4.36 per share a year ago. These ...